Sequential designs for ordinal phase I clinical trials.

Sequential designs for phase I clinical trials which incorporate maximum likelihood estimates (MLE) as data accrue are inherently problematic because of limited data for estimation early on. We address this problem for small phase I clinical trials with ordinal responses. In particular, we explore the problem of the nonexistence of the MLE of the logistic parameters under a proportional odds model with one predictor. We incorporate the probability of an undetermined MLE as a restriction, as well as ethical considerations, into a proposed sequential optimal approach, which consists of a start-up design, a follow-on design and a sequential dose-finding design. Comparisons with nonparametric sequential designs are also performed based on simulation studies with parameters drawn from a real data set.

[1]  Sequential Designs for Logistic Phase I Clinical Trials , 2006, Journal of biopharmaceutical statistics.

[2]  M. Silvapulle,et al.  Existence of Maximum Likelihood Estimates in Regression Models for Grouped and Ungrouped data , 1986 .

[3]  J. Kiefer,et al.  The Equivalence of Two Extremum Problems , 1960, Canadian Journal of Mathematics.

[4]  C. F. Wu,et al.  Efficient Sequential Designs with Binary Data , 1985 .

[5]  Michael Woodroofe,et al.  Isotonic smoothing splines under sequential designs , 1994 .

[6]  L. Haines,et al.  Bayesian Optimal Designs for Phase I Clinical Trials , 2003, Biometrics.

[7]  V. Fedorov,et al.  Adaptive designs for dose-finding based on efficacy–toxicity response , 2006 .

[8]  E. Eisenhauer,et al.  Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Nancy Flournoy,et al.  Quantile estimation following non-parametric phase I clinical trials with ordinal response. , 2004, Statistics in medicine.

[10]  J Whitehead,et al.  Bayesian decision procedures based on logistic regression models for dose-finding studies. , 1998, Journal of biopharmaceutical statistics.

[11]  Richard A. Lockhart Editor's report/rapport du rédacteur en chef , 2003 .

[12]  S Zacks,et al.  Cancer phase I clinical trials: efficient dose escalation with overdose control. , 1998, Statistics in medicine.

[13]  L. J. Wei,et al.  Statistical Inference with Data-Dependent Treatment Allocation Rules , 1990 .

[14]  William F. Rosenberger,et al.  Optimal design for the proportional odds model , 2003 .

[15]  R Simon,et al.  Accelerated titration designs for phase I clinical trials in oncology. , 1997, Journal of the National Cancer Institute.